Navigation Links
Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
Date:10/30/2008

expenses increased 21 percent to $3.4 million for the third quarter of 2008, from $2.8 million for the third quarter of 2007. G&A expenses increased 32 percent to $11.3 million for the nine months ended September 30, 2008, from $8.6 million for the same period in 2007. The increases in G&A expenses for the three months ended September 30, 2008, were due primarily to higher stock-based compensation expense, higher costs for consultants and increased legal costs. The increases in G&A expenses for the nine months ended September 30, 2008, are due primarily to stock-based compensation expense and increased personnel costs.

2008 Goals and Objectives

During the remainder of 2008 and into 2009, we anticipate further important progress in the development of picoplatin. We intend to:

-- Continue to advance our pivotal Phase 3 SPEAR trial in SCLC toward commercialization, targeted in 2010;

-- Announce final top-line data from our Phase 1 oral picoplatin study; and

-- Present additional efficacy and safety data from our ongoing Phase 2 trials in CRC and HRPC at medical conferences in 1Q09 and throughout next year.

Conference Call Details

To participate in today's live 2 p.m. Pacific Time/5 p.m. Eastern Time call by telephone, please dial 877-419-6593 from the U.S. or 1-719-325-4885 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum thera
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... Lalvani and colleagues from University of Oxford, UK has found ... which BCG vaccination which is administered world wide for children’s ... an effective treatment in patients with TB infection. The researchers ... children, of which 770 children’s had BCG scar, as the ...
... as 150 million Indians, who comprise about 15 percent ... arthritis, according to latest reports by doctors//. This figure ... the meeting held in conjunction with World Arthrirtis Day. ... is also being conducted to create awareness on handling ...
... A study conducted to evaluate the effectiveness of environmental ... intervention program would be a cost effective way to ... study was conducted among 900 children suffering from mild ... on six major classes of allergens that trigger asthma ...
... researchers at the University of Minnesota have managed to create ... laboratory in what could be a revolutionary method of treating ... discovery is to appear in the October 15 issue of ... "natural killer" cells from the stem cells in the laboratory. ...
... needed. Ideally, such products should have antimicrobial and ... a role in the reduction of sexually// transmitted ... ,Most of the spermicidal products being ... ingredient, which do not provide any protection against ...
... the inability of a man to achieve or maintain an ... his partner. Most men experience this at some point in ... affected by it. Some men, however, experience chronic, complete ED ... to a new study in the October 18 issue of ...
Cached Medicine News:Health News:BCG vaccine for both Protection and treatment of Tuberculosis 2Health News:Dermaseptins: Potent vaginal contraceptives 2Health News:Erectile dysfunction: an early warning sign of clinically silent coronary artery disease? 2
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... N.C. , Feb. 4 Gorbec Pharmaceutical ... prescription pharmaceutical products, is opening a GMP-compliant analytical laboratory ... expand Gorbec,s current services for analytical method development and ... its U.S. customer base as well as develop a ...
... , Feb. 4 Genoptix, Inc. (Nasdaq: GXDX ), ... report its financial results for the fourth quarter and full-year 2009 after ... 2010 . , A conference call hosted by President and CEO, ... will take place on the same day at 2:00pm PST ...
Cached Medicine Technology:Gorbec Pharmaceutical Services, Inc. Announces the Launch of Its GMP Analytical Laboratory in China 2Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 2Genoptix, Inc. to Announce Fourth Quarter and Full-Year 2009 Financial Results 3
...
...
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in ...
Medtronic neurosurgery external drainage and monitoring (EDM) products meet a variety of needs for CSF drainage and monitoring....
Medicine Products: